Lilly's weight loss pills were accused of rebounding after discontinuation, and the company's stock price plummeted at one point
桃花朵朵149
发表于 2023-12-12 14:11:53
1340
0
0
According to the Red Star Capital Bureau, the stock price of weight loss drug giant LY. US fell at the beginning of trading on December 11th local time, with a drop of over 5% during the trading session. The subsequent decline has eased. As of the close, it fell 2.34% to $584.04 per share, with a total market value of $554.4 billion.
On the news side, according to a report by Caixin, a study published in the Journal of the American Medical Association showed that after using Eli Lilly's weight loss drug Zepbound for about eight months and discontinuing administration, the weight of the subjects slowly rebounded, and the weight lost increased by half again one year later.
Specifically, 670 patients lost 20.9% of their weight after approximately 8 months of using Zepbound. Afterwards, half of the patients continued to receive Zepbound for another year, while the other half received placebo.
The data shows that patients who continued to receive Zepbound had an average weight loss of 5.5%, while the other half of patients who received placebo had an average weight gain of 14%.
Red Star Capital Bureau noted that on November 9, Lilly announced that the company's tirzepatide injection (trade name: Zepbound) was approved by the U.S. Food and Drug Administration (FDA) and was applicable to long-term weight management of overweight adults who were obese or had at least one complication (such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease).
The main ingredient of Zepbound is Tilpatide, which, according to Lilly, is the first and currently the only approved drug that can activate two types of intestinal trypsin receptors (GIP and GLP-1), targeting the root cause of weight gain. According to reports, Novo Nordisk's (NVO.US) semaglutide only targets GLP-1.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- After being shorted by Hindenburg, the performance report was postponed and the stock price of Supermicro Computer plummeted by 26%
- Q2 performance growth is strong, and the stock price of Yaduo Group has risen by 13.32%
- ASME's stock price fell by 6%, and other chip stocks followed suit and fell
- Apple's stock price drops by 1%
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- Trump Media's stock price has fallen by 70% since going public, experts say valuation is still 'unreasonably high'!
- Global markets: European and American stock markets close down, Nasdaq falls more than 1%, ASML stock price drops more than 16%
- Top 20 US Stock Transactions: Netflix's Strong Performance, Stock Price Rises 11% to Record High
- Google's third quarter report is expected to reveal significant fluctuations in stock price, which may be difficult to avoid
- Apple invests $1.5 billion to increase its stake in satellite communications, causing a surge in global satellite stock prices
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 昨天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 6 小时前
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 7 小时前
- 支持
- 反对
- 回复
- 收藏